Longevity
MOTS-c
aka Mitochondrial ORF of the 12S rRNA type-c · Mitochondrial-derived peptide (MDP) · MOTSc · MOTS-C · mots c · exercise mimetic · mitochondrial peptide
Grade
A tiny peptide your own mitochondria produce during exercise, promising for metabolism in mice, but in humans only measured as a biomarker rather than proven to work as an injected drug.
- Class
- Mitochondrial-derived peptide (MDP); endogenous mitochondrial-encoded signalling peptide
- Evidence
- Grade D · Animal data only
- Sport / WADA
- Not specifically named on the WADA Prohibited List, but as an exercise-mimetic peptide affecting metabolism it sits in a category of interest; athletes subject to testing should seek explicit guidance rather than assume it is permitted.
- Last reviewed
- 2026-06
Grade D · Animal data only
Why this grade
The therapeutic story rests almost entirely on rodent and cell studies. In mice, administered MOTS-c improves insulin sensitivity, resists diet-induced obesity and extends physical capacity into old age. The genuine human data is observational, not interventional. Circulating and muscle MOTS-c rises with exercise and falls in metabolic disease, but that tells us it is a biomarker, not that injecting it works. A first interventional human study (Phase 2a, NCT07505745) only registered in 2025 and has reported no efficacy results. As a treatment in humans, the evidence is effectively preclinical. Not an F because the mechanism is real and a registered controlled trial now exists. Firmly D until that trial reads out with positive data.
What is it?
Your cells contain mitochondria, the little batteries that turn food into energy. Those batteries also make a tiny messenger called MOTS-c that tells the body to burn fuel more efficiently, a bit like the signals you get from exercising. In mice, giving extra MOTS-c kept them leaner, steadied their blood sugar and let them stay physically stronger into old age. That is why people got excited about it for ageing and metabolism. Almost all of that evidence is in animals. In humans we mostly know that MOTS-c naturally goes up when you exercise and tends to be low in people with diabetes. That is a useful clue, but very different from proving that buying and injecting it makes a healthy person healthier. A proper human trial has only just started, so right now this is a hopeful science story, not a proven treatment.
It is like a fitness-tracker reading that reliably climbs when you exercise and dips when you are metabolically unwell. That makes it a great dashboard light but nobody has yet shown that forcing the needle up with a syringe makes the engine run better. In mice it does; in humans we have only watched the dial, not yet turned it.
How is it meant to work?
Encoded within the mitochondrial 12S rRNA, MOTS-c is a 16-amino-acid mitochondrial-derived peptide that interferes with the folate one-carbon cycle and de novo purine synthesis, causing AICAR accumulation and activating the cellular energy sensor AMPK. This promotes glucose uptake via GLUT4 and a metabolic state resembling exercise. Under metabolic stress it translocates to the nucleus, where it regulates stress-response and antioxidant gene programmes including NRF2-linked pathways. Skeletal muscle is the principal target tissue.
What's it studied for?
Research contexts. Not proven uses, and not recommendations.
Does the human evidence stack up?
Genuine human evidence is observational, not interventional. Studies show MOTS-c is induced in skeletal muscle and rises in the circulation after acute exercise, and that lower circulating levels correlate with insulin-resistance markers (HOMA-IR, HbA1c) and with type 2 diabetes, PCOS and other metabolic conditions. These establish MOTS-c as a biomarker and plausible target but do not show that administering it benefits people. As of mid-2026 the first registered controlled interventional efficacy trial (Phase 2a, NCT07505745, prediabetes with overweight/obesity) is registered and getting underway but has not reported results. No efficacy endpoint has yet been met in any human trial.
What could go wrong?
- !Human efficacy is unproven. To date the only human data are observational or biomarker studies; no completed controlled trial shows benefit from administering it.
- !Everything sold to the public is unlicensed research chemical material labelled 'not for human consumption'. It is not a medicine and has no MHRA marketing authorisation.
- !Grey-market purity, sterility, dose accuracy and endotoxin contamination are real risks with injectable research peptides. Injection itself carries infection and abscess risk.
- !Long-term safety in humans is essentially unknown. Immunogenicity and the effects of chronic supraphysiological dosing are unstudied.
- !Marketing routinely extrapolates striking mouse longevity and metabolic data directly to humans, a classic overclaim the actual evidence does not support.
- !Circulating MOTS-c measurement by antibody has been debated within the science, complicating the biomarker literature.
Is it legal in the UK?
Not a licensed medicine in the UK. MOTS-c has no MHRA marketing authorisation and is not approved for any indication. It is an investigational or preclinical agent. It is not a controlled drug, but selling or supplying it for human use would breach the Human Medicines Regulations 2012; vendors therefore market it as a research chemical or reference standard labelled not for human consumption. There is no legitimate UK prescription route. As an endogenous metabolic or exercise-mimetic peptide it also attracts anti-doping interest; anyone subject to sport testing should check current WADA guidance. For the general public the key fact is that it is an unlicensed, unregulated product.
Key trials
- NCT07505745· Phase 2a· Registered 2025; getting underway as of 2026, with no efficacy results reported
MOTS-c (MDP) subcutaneous injection in insulin resistance, prediabetes and overweight/obesity
Randomised, double-blind, placebo-controlled; primary endpoint OGTT-derived insulin sensitivity (Matsuda index); secondary endpoints include HbA1c, fasting/2-hour glucose and safety/immunogenicity.
Sources
- 01The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance — Lee C, Zeng J, Drew BG, et al., Cell Metabolism (2015)
Landmark discovery paper: identifies MOTS-c, AMPK activation via the folate cycle, and metabolic effects in mice.
- 02The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress — Kim KH, Son JM, Benayoun BA, Lee C, Cell Metabolism (2018)
Establishes MOTS-c nuclear translocation and its role as an AMPK-dependent transcriptional regulator of stress-response genes.
- 03MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis — Reynolds JC, Lai RW, Woodhead JST, et al., Nature Communications (2021)
Shows exercise induces endogenous MOTS-c in human muscle and circulation; intermittent administration improves physical capacity in aged mice.
- 04MOTS-c: review of mechanism and the preclinical-versus-human evidence gap for the mitochondrial-derived peptide, PubMed (review literature) (2022)
Representative review summarising mechanism and the gap between striking preclinical data and limited human evidence. PubMed search link given rather than a single identifier to avoid citing an uncertain ID.
- 05MOTS-c (MDP), subcutaneous, in insulin resistance / prediabetes with overweight/obesity (Phase 2a) (2025)
First registered controlled interventional human efficacy trial; OGTT-derived Matsuda index primary endpoint; no results reported at time of writing.
Related
Stay posted
Follow MOTS-c
We'll email you only when MOTS-c's evidence actually changes — a new human trial, a grade change, a safety signal. No spam, nothing for sale.